On November 27, 2025 Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, reported a co-development collaboration to evaluate the combination of Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s Carteyva—a CD19- directed autologous CAR-T cell therapy—for patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration includes preclinical in vitro and in vivo studies, followed by a Phase 1 investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. The approach utilizes Imugene’s CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies—a transformative "mark and kill" strategy.

"This collaboration allows us to validate our onCARlytics platform in combination with an approved autologous CAR-T product," said Leslie Chong, Managing Director and CEO of Imugene. "We believe Carteyva which is already approved in blood cancer is an ideal choice, and this initiative enables us to generate impactful data efficiently while exploring a breakthrough treatment paradigm for solid tumours."

With clear go/no-go decision points, and milestones, the collaboration ensures disciplined capital allocation while enabling strategic flexibility.

(Press release, Imugene, NOV 27, 2025, https://mcusercontent.com/e38c43331936a9627acb6427c/files/2f4974d7-399e-d9a4-0ddd-55588cedec81/Strategic_Collaboration_with_JW_Therapeutics.pdf [SID1234660990])